
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
Perindopril: Clinical Profile of a Unique ACE Inhibitorover 27 years ago
Issues in Vascular Complianceover 27 years ago
Selected Abstracts





